Morgan Stanley’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.8M | Buy |
1,280,119
+400,975
| +46% | +$3.82M | ﹤0.01% | 3506 |
|
|
2025
Q4 | $10.7M | Sell |
879,144
-1,586,532
| -64% | -$19.3M | ﹤0.01% | 3552 |
|
|
2025
Q3 | $28.8M | Sell |
2,465,676
-106,047
| -4% | -$1.27M | ﹤0.01% | 2529 |
|
|
2025
Q2 | $23.9M | Buy |
2,571,723
+383,245
| +18% | +$3M | ﹤0.01% | 2623 |
|
|
2025
Q1 | $16M | Buy |
2,188,478
+365,553
| +20% | +$2.81M | ﹤0.01% | 2916 |
|
|
2024
Q4 | $15.6M | Buy |
1,822,925
+238,750
| +15% | +$2.33M | ﹤0.01% | 3001 |
|
|
2024
Q3 | $13.8M | Buy |
1,584,175
+421,694
| +36% | +$3.48M | ﹤0.01% | 3161 |
|
|
2024
Q2 | $7.95M | Sell |
1,162,481
-210,554
| -15% | -$1.3M | ﹤0.01% | 3495 |
|
|
2024
Q1 | $12.5M | Buy |
1,373,035
+726,725
| +112% | +$5.16M | ﹤0.01% | 3163 |
|
|
2023
Q4 | $2.88M | Buy |
646,310
+399,885
| +162% | +$1.18M | ﹤0.01% | 4735 |
|
|
2023
Q3 | $774K | Buy |
246,425
+13,660
| +6% | +$55.9K | ﹤0.01% | 4945 |
|
|
2023
Q2 | $1.2M | Sell |
232,765
-948,938
| -80% | -$5.64M | ﹤0.01% | 4728 |
|
|
2023
Q1 | $6.23M | Buy |
1,181,703
+753,831
| +176% | +$3.58M | ﹤0.01% | 3591 |
|
|
2022
Q4 | $1.2M | Buy |
427,872
+239,559
| +127% | +$793K | ﹤0.01% | 4759 |
|
|
2022
Q3 | $782K | Sell |
188,313
-40,828
| -18% | -$206K | ﹤0.01% | 5029 |
|
|
2022
Q2 | $920K | Buy |
229,141
+7,480
| +3% | +$28.3K | ﹤0.01% | 5065 |
|
|
2022
Q1 | $1.1M | Sell |
221,661
-200,711
| -48% | -$1.11M | ﹤0.01% | 4927 |
|
|
2021
Q4 | $2.94M | Sell |
422,372
-226,443
| -35% | -$1.76M | ﹤0.01% | 4259 |
|
|
2021
Q3 | $6.49M | Buy |
648,815
+156,948
| +32% | +$1.76M | ﹤0.01% | 3404 |
|
|
2021
Q2 | $6.97M | Buy |
491,867
+157,541
| +47% | +$2.39M | ﹤0.01% | 3418 |
|
|
2021
Q1 | $5.49M | Buy |
334,326
+72,409
| +28% | +$1.39M | ﹤0.01% | 3308 |
|
|
2020
Q4 | $5.42M | Sell |
261,917
-2,710
| -1% | -$40.2K | ﹤0.01% | 3175 |
|
|
2020
Q3 | $2.01M | Buy |
264,627
+68,514
| +35% | +$569K | ﹤0.01% | 3653 |
|
|
2020
Q2 | $1.63M | Buy |
196,113
+45,981
| +31% | +$305K | ﹤0.01% | 3786 |
|
|
2020
Q1 | $743K | Sell |
150,132
-88,589
| -37% | -$437K | ﹤0.01% | 4147 |
|
|
2019
Q4 | $943K | Buy |
238,721
+50,335
| +27% | +$175K | ﹤0.01% | 4577 |
|
|
2019
Q3 | $573K | Buy |
188,386
+11,922
| +7% | +$53.3K | ﹤0.01% | 4618 |
|
|
2019
Q2 | $777K | Sell |
176,464
-54,153
| -23% | -$200K | ﹤0.01% | 4366 |
|
|
2019
Q1 | $916K | Sell |
230,617
-93,663
| -29% | -$377K | ﹤0.01% | 4171 |
|
|
2018
Q4 | $1.29M | Buy |
324,280
+69,315
| +27% | +$382K | ﹤0.01% | 4093 |
|
|
2018
Q3 | $1.75M | Sell |
254,965
-22,831
| -8% | -$143K | ﹤0.01% | 4107 |
|
|
2018
Q2 | $1.88M | Buy |
277,796
+5,641
| +2% | +$38.8K | ﹤0.01% | 4137 |
|
|
2018
Q1 | $1.77M | Buy |
272,155
+13,230
| +5% | +$74.5K | ﹤0.01% | 4116 |
|
|
2017
Q4 | $1.15M | Sell |
258,925
-11,363
| -4% | -$58K | ﹤0.01% | 4443 |
|
|
2017
Q3 | $1.67M | Sell |
270,288
-128,782
| -32% | -$829K | ﹤0.01% | 4041 |
|
|
2017
Q2 | $3.7M | Sell |
399,070
-205,566
| -34% | -$1.99M | ﹤0.01% | 3202 |
|
|
2017
Q1 | $5.61M | Buy |
604,636
+275,950
| +84% | +$2.3M | ﹤0.01% | 2749 |
|
|
2016
Q4 | $2.75M | Sell |
328,686
-244,623
| -43% | -$1.9M | ﹤0.01% | 3626 |
|
|
2016
Q3 | $3.94M | Buy |
573,309
+474,703
| +481% | +$2.89M | ﹤0.01% | 2900 |
|
|
2016
Q2 | $488K | Buy |
98,606
+75,784
| +332% | +$751K | ﹤0.01% | 4437 |
|
|
2016
Q1 | $220K | Buy |
22,822
+16,572
| +265% | +$126K | ﹤0.01% | 4917 |
|
|
2015
Q4 | $59K | Sell |
6,250
-738
| -11% | -$7.97K | ﹤0.01% | 5643 |
|
|
2015
Q3 | $98K | Sell |
6,988
-10,616
| -60% | -$213K | ﹤0.01% | 5429 |
|
|
2015
Q2 | $370K | Sell |
17,604
-1,038
| -6% | -$25.7K | ﹤0.01% | 4914 |
|
|
2015
Q1 | $783K | Buy |
18,642
+3,294
| +21% | +$108K | ﹤0.01% | 4318 |
|
|
2014
Q4 | $361K | Sell |
15,348
-50,836
| -77% | -$855K | ﹤0.01% | 4897 |
|
|
2014
Q3 | $992K | Buy |
+66,184
| New | +$979K | ﹤0.01% | 4034 |
|
Other funds holding OCUL
DTC
ACA
SR
VA
VCM
Morgan Stanley's OCUL Position: Q1 2026 in Review
Morgan Stanley increased its Ocular Therapeutix (OCUL) stake by 46% in Q1 2026, buying an estimated $3.82M and bringing the position to 1,280,119 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3506.
Morgan Stanley first reported a position in OCUL in Q3 2014 and has held it in 47 quarters since. The position peaked at $28.8M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.
- Morgan Stanley held 1,280,119 shares of Ocular Therapeutix worth $10.8M as of Q1 2026.
- Morgan Stanley bought 400,975 Ocular Therapeutix shares in Q1 2026, an estimated $3.82M.
- Ocular Therapeutix made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3506 holding.
- Morgan Stanley first reported a position in Ocular Therapeutix in Q3 2014 and has held it in 47 quarters since.
- Morgan Stanley's Ocular Therapeutix position peaked at $28.8M in Q3 2025.
- 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.